文献速递胸部肿瘤

肺肉瘤样癌的分子分型提示新的治疗机会

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.
PubMed 文献 · Ann Oncol · 2017-01-01

研究对15例肺肉瘤样癌(SC)患者及10例既往发表病例进行全外显子测序,基于突变特征进行聚类分析,发现SC可分为Csig4和Csig2-3-13两个簇,两簇在MAPK通路突变、PD-L1表达、MET等基因改变及总生存上存在差异,提示Csig4可能适合免疫检查点抑制剂、Csig2-3-13可能适合特定靶向药物。

要点

  • 基于突变特征,肺肉瘤样癌可分为Csig4和Csig2-3-13两个分子簇。
  • Csig4簇MAPK通路突变更常见且PD-L1表达更强,MET改变仅见于Csig2-3-13簇。
  • Csig2-3-13簇患者总生存优于Csig4簇(中位>45个月 vs 7个月,P=0.001)。

核心结论

  • 研究提示肺肉瘤样癌至少存在两个具有不同突变过程、基因改变和PD-L1表达的分子簇。
  • Csig4簇潜在治疗方向为免疫检查点抑制剂,Csig2-3-13簇为特定靶向药物。
  • 作者认为这些发现应鼓励临床医生对肺肉瘤样癌患者开展超越MET外显子14改变的广泛分子和免疫检测。

研究设计与样本

  • 对15例肺肉瘤样癌患者进行全外显子测序,并纳入10例既往发表病例的数据。
  • 采用层次聚类和共识非负矩阵分解基于突变特征对样本进行分类。

主要发现

  • 在两个系列中,肺肉瘤样癌分布于两个簇:Csig4(以突变特征4为特征)和Csig2-3-13(以突变特征2、3和13为特征)。
  • Csig4簇MAPK通路突变比Csig2-3-13簇更频繁(合并系列:10/14 vs 2/11,P<0.05)。
  • Csig4簇PD-L1表达更强(本研究系列:6/9 vs 1/6,P=0.12)。
  • MET改变仅见于Csig2-3-13簇(合并系列:5/11 vs 0/14,P=0.009),BRCA1/BRCA2突变亦仅见于该簇(3/11 vs 0/15),另见EGFR突变(n=1)和IDH1突变(n=1)。
  • Csig2-3-13簇患者总生存优于Csig4簇患者(中位:>45个月 vs 7个月,P=0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter- and intratumor heterogeneity. However, molecular classification is currently focused on activating MET mutations. We sought to better characterize the molecular diversity of SC using mutational signatures that reflect different mutational processes, such as tobacco-associated adducts (signature 4), BRCA1/BRCA2 deficiency (signature 3), or APOBEC enzyme deamination (signatures 2 and 13). PATIENTS AND METHODS: Whole-exome sequencing was carried out in 15 SC patients and on data from 10 previously published cases. Hierarchical clustering and consensus non-negative matrix factorization were carried out for samples classification based on mutational signatures. RESULTS: In the two series, SC distributed between two clusters (C): Csig4 (characterized by signature 4) and Csig2-3-13 (signatures 2, 3, and 13). Csig4 exhibited more frequent MAPK pathway mutations than Csig2-3-13 (pooled series: n = 10/14 versus 2/11, P < 0.05, respectively) and stronger PD-L1 expression (our series: n = 6/9 versus 1/6, P = 0.12). MET alterations were only found in Csig2-3-13 (pooled series: n = 5/11 versus 0/14, P = 0.009), as well as BRCA1/BRCA2 (n = 3/11 versus 0/15), EGFR (n = 1), and IDH1 (n = 1) mutations. Csig2-3-13 patients had better overall survival than Csig4 patients (median: >45 versus 7 months, respectively, P = 0.001). CONCLUSIONS: Our study suggests that SC presents at least two clusters comprising different mutational processes, gene alterations, and PD-L1 expression. New potential treatment possibilities are immune checkpoint inhibitors in Csig4 and specific targeted agents in Csig2-3-13. These findings should encourage clinicians to conduct broad molecular and immunological testing in SC patients beyond MET exon 14 alterations.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pécuchet N, Vieira T, Rabbe N, et al. Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Ann Oncol. 2017. PMID: 28419182. doi:10.1093/annonc/mdx162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。